Nociceptin (orphanin FQ) is a novel, opioid-like, heptadecapeptide that is an endogenous ligand for the opioid receptor-like (ORL 1 ) receptor. Unlike classical opioids, nociceptin can produce hyperalgesia when injected intracerebroventricularly into mice. Despite this, nociceptin has been reported to decrease transmitter release, activate an inwardly rectifying K ϩ conductance, and suppress high-voltage-activated Ca 2ϩ channel conductances (HVA g Ca ) in much the same way as -, ␦-, and -opioids. We report an action of nociceptin that is not shared by morphine: the suppression of low-voltage-activated, transient calcium (barium) current (I Ba,T ) in acutely dissociated rat dorsal root ganglion (DRG) neurons (EC 50 ϭ 100 nM). This effect was reflected as inhibition of bursts of action potentials that can be evoked in "medium-sized" DRG neurons. Experiments with GTP-␥-S (100 M), GDP-␤-S (2 mM), or aluminum fluoride (AlF 3 ) (100 M) in the patch pipette failed to provide evidence for G-protein involvement in nociceptin-induced I Ba,T suppression. By contrast, both morphine and nociceptin suppressed HVA g Ca , and the latter response was affected by intracellular GTP-␥-S, GDP-␤-S, and AlF 3 in ways that confirmed G-protein involvement. The selective effect of nociceptin on I Ba,T may therefore be relevant to understanding why its behavioral actions differ from those of other opioids. This G-proteinindependent effect of the action of nociceptin may reflect a new general mechanism of action for opioid peptides within the nervous system.
The heptadecapeptide nociceptin (orphanin FQ) is an endogenous ligand for the opioid receptor-like (ORL 1 ) receptor (Meunier et al., 1995; Reinscheid et al., 1995; Nothacker et al., 1996) . This substance has attracted considerable attention, because unlike conventional opioids it does not produce analgesia when injected intracerebroventricularly into mice; in fact, nociceptin produces hyperalgesia in a tail-flick assay (Meunier et al., 1995; Reinscheid et al., 1995) . Despite this, the cellular actions of nociceptin appear similar to those of -, ␦-, and -opioids. Opioids suppress neurotransmitter release (Jessell and Iversen, 1977; MacDonald and Nelson, 1978; Cherubini and North, 1985; Hori et al., 1992; , and -, ␦-, or -opioids attenuate high-voltage-activated C a 2ϩ channel conductances (HVA g C a ) (Hescheler et al., 1987; Surprenant et al., 1990; Schroeder et al., 1991; Moises et al., 1994a,b; Womack and McC leskey, 1995) and activate an inwardly rectif ying K ϩ conductance ( g K IR ) (North et al., 1987; Williams et al., 1988; Grudt and Williams, 1993) . Similarly, nociceptin suppresses transmitter release in the periaqueductal gray matter and in the superficial dorsal horn of neonatal rat spinal cord (Liebel et al., 1997) . It also inhibits H VA g C a in hippocampal neurons (Knoflach et al., 1996) and in a neuroblastoma cell line (Connor et al., 1996b) . Nociceptin activates g K IR in dorsal raphe neurons (Vaughan and Christie, 1996) , in midbrain periaqueductal gray neurons , and in locus coeruleus neurons (Connor et al., 1996a) .
The molecular mechanisms underlying opioid actions are often studied by examining their effects on g C a in the cell bodies of sensory neurons that lie in dorsal root ganglia (DRG) (Schroeder et al., 1991; Moises et al., 1994a,b; Wilding et al., 1995; Womack and McCleskey, 1995) . We report here an action of nociceptin on rat DRG neurons that is not shared by the classic analgesic opioid morphine. Although both agonists suppress HVA g C a by a Gprotein-dependent mechanism, only nociceptin affects the lowvoltage-activated (LVA), transient I C a (T-current, I C a,T ). This effect, which does not seem to involve G-protein activation, is reflected in the attenuation of action potential afterdepolarization and multiple spike discharge in "medium-sized" DRG cells. Whereas I C a,N is normally associated with neurotransmitter release (DeWaard et al., 1996) , I C a,T is responsible for generating repetitive or bursting discharges, for boosting Ca 2ϩ entry, and for generation of low-threshold spikes (Huguenard, 1996) . The selective suppression of I C a,T by nociceptin may therefore be relevant to understanding why its behavioral actions differ from those of morphine. This novel action supports the idea that certain effects of opioid peptides may be generated without the involvement of G-proteins (Twitchell and Rane, 1994; Brauneis et al., 1996) .
MATERIALS AND METHODS
Male Sprague Dawley rats (180 -300 gm) were decapitated in a small animal guillotine, and neurons from L 4 and L 5 DRG were dissociated using a trypsin /collagenase/ DNase/trypsin inhibitor procedure as described by White et al. (1989) . Dissociated cells were plated into petri dishes, superf used with various extracellular solutions at ϳ2 ml /min, and used for recording within 2-10 hr. Whole-cell voltage recordings were made using an Axoclamp 1B amplifier in bridge-balance mode, and action potentials (APs) were evoked by passing 2-5 msec depolarizing currents through the recording electrode. Single-electrode, discontinuous voltage-clamp mode was used to record I C a with Ba 2ϩ as charge carrier (I Ba ). Borosilicate glass patch electrodes had DC resistances of 4 -6 M⍀ for AP recording or 1-3 M⍀ for current recording. Because the dissociated cells were relatively small and spherical, currents of 10 nA or more could be recorded with little or no voltage control problems. I Ba tails recorded at Ϫ40mV were described by a single exponential f unction. Because Ba 2ϩ was used as a charge carrier, the slow tail currents that result from activation of C a 2ϩ -dependent C l Ϫ conductances ( g C l,C a ) (Mayer, 1985) were not observed. A P/4 leak subtraction paradigm was used when necessary.
Under bridge-balance current-clamp, input capacitance (C in ) was calculated from the input resistance (R in ) and the membrane time constant ( m ) using the equation m ϭ C in R in . Under voltage clamp, C in was measured by integrating the area of capacitative current transients that were generated by 10 mV commands (⌬V). This yielded the charge Q that is related to C in by Q ϭ VC in . DRG neurons were classified into three groups according to their size and AP shape. "Large" cells were defined as those with AP duration Ͻ3 msec and C in Ͼ90 pF; "medium" cells had an AP duration of 3-5 msec and C in of 70 -90 pF; and "small" cells had an AP duration Ͼ5 msec and C in Ͻ70 pF. Both medium and small cells exhibited a "hump" or "shoulder" on the falling phase of their AP (Abdulla and Smith, 1997) . Spike duration (AP width) was measured at half-maximum amplitude. Because T-currents (I Ba,T ) were encountered most frequently in the mediumsized cells (Scroggs and Fox, 1992) , all experiments were performed on cells within the 70 -90 pF size range, 40% of which had a robust I Ba,T .
Only cells with "giant" I Ba,T (Ͼ1 nA) (Rusin and Moises, 1995) were selected for analysis.
For AP recording, external solution contained (in mM): 150 NaC l, 5 KC l, 2.5 C aC l 2 , 1 MgC l 2 , 10 H EPES-NaOH, pH 7.4, and 10 D-glucose; osmolarity, 330 -340 mOsm. Internal solution contained (in mM): 130 potassium gluconate, 2 Mg-ATP, 0.3 Na-GTP, 11 EGTA, 10 H EPES-KOH, pH 7.2, and 1 C aC l 2 ; osmolarity, 310 -320 mOsm. For recording LVA and H VA I Ba , external solution contained (in mM): 160 TEA-C l, 10 H EPES, 2 BaC l 2 , 10 glucose, and 200 nM TTX, adjusted to pH 7.4 with TEA-OH; internal solution contained (in mM): 120 C sC l 2 , 5 Mg-ATP, 0.4 Na-GTP, 10 EGTA, 20 H EPES-C sOH, pH 7.2. E xcept where stated otherwise, I Ba,T was recorded in response to a command to Ϫ40 mV, and H VA currents (N, L, P, and presumptive Q types) Moises, 1995, DeWaard et al., 1996) were activated by commands to Ϫ10 mV. The holding potential (V h ) for voltage-clamp experiments was Ϫ90 mV.
Drugs were applied by bath superf usion using a tap system that had an exchange time of ϳ90 sec. Nociceptin (rat or human; Phe-Gly-GlyPhe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln) was from Peptide Institute Inc. (L ouisville, K Y); naloxone hydrochloride, naloxone benzoylhydrazone (nalbzoh), and guanosine-5Ј-O-(3-thiodiphosphate) (GTP-␥-S; trilithium salt) were from Research Biochemical International (Natick, M A), and guanosine-5Ј-O-(2-thiodiphosphate) (GDP-␤-S; trilithium salt) was from C albiochem (San Diego, CA) or from RBI. All other chemicals were from Sigma (St. L ouis. MO).
Data were acquired and analyzed using Pclamp software (version 
RESULTS

Suppression of T-current by nociceptin
Nociceptin (0.01-1.0 M) suppressed I Ba,T in all cells tested (n Ͼ 100). Figure 1 A 1 illustrates almost complete suppression of I Ba,T by 1 M nociceptin in a medium-sized DRG neuron. An equal concentration of morphine produced only a small (Ͻ10%) suppression of I Ba,T in the same cell ( Fig. 1 A 2 ). Morphine (up to 10 M) produced no more than 20% suppression of I Ba,T in 18 of 67 cells tested, and the remainder (49) were unaffected. Nociceptininduced inhibition was reflected in attenuation of I Ba,T tails recorded at Ϫ60 mV ( Fig. 1 B) . The preferential blockade of I Ba,T by nociceptin is illustrated further by the current-voltage ( I-V ) curves shown in Figure  1C ,D. The presence of I Ba,T is seen as an inflection on the descending part of the curve between Ϫ50 and Ϫ25 mV (Fox et al., 1987) . This inflection is attenuated in the presence of nociceptin ( Fig. 1C) but not in the presence of morphine (Fig. 1 D) . At more positive voltages, N-, L -, P-, and presumptive Q-type conductances are activated (Fox et al., 1987; Rusin and Moises, 1995) . Components of these H VA conductances were attenuated by both nociceptin and morphine. This is clear from the I-V curves shown in Figure 1C ,D and from the data records in Figure  2 A 1 ,B 1 .
The EC 50 for nociceptin-induced suppression of I Ba,T from the log-concentration-response relationship ( Fig. 1 E) was 100 nM with a Hill coefficient of 1.0 (Fig. 1 F) . Nociceptin (1 M) completely blocked I Ba,T in 22 of 77 cells tested. This contrasted with the actions of both nociceptin and morphine on H VA conductances, in which suppression rarely exceeded 70%.
Pharmacology of DRG T-current
The current that was inhibited by nociceptin was clearly I Ba,T , because it was almost completely blocked by Ni 2ϩ (100 M) (DeWaard et al., 1996) yet was reduced by Ͻ25% by Cd 2ϩ (100 M; n ϭ 4). By contrast, HVA conductances were selectively blocked by Cd 2ϩ (100 M) and were reduced by Ͻ25% by Ni 2ϩ (100 M; n ϭ 4). In another experiment, we found that 20 M Ni 2ϩ produced clear suppression of I Ba,T , with negligible effect on HVA I Ba .
I Ba,T was not affected by -conotoxin GVIA (1 M; n ϭ 3), and nifedipine (2 M; n ϭ 3) produced Ͻ10% suppression.
Ethosuximide, a drug that is used in the management of absence seizures, has been reported to inhibit I Ba,T in thalamic relay (Coulter et al., 1990; Huguenard and Prince, 1994) and reticular neurons (Huguenard and Prince, 1994) . This substance was without effect on I Ba,T in DRG neurons (500 M; n ϭ 2).
Pharmacology of nociceptin-induced T-current suppression
Effects mediated via ORL 1 receptors are unaffected or relatively insensitive to inhibition by the broad spectrum -, ␦-, andopioid antagonist naloxone (Connor et al., 1996a,b; Faber et al., 1996) . In agreement with this, naloxone (up to 1 M) failed to antagonize the suppression of I Ba,T by nociceptin (n ϭ 3) (Fig.  3A 1 , A 2 ). On the other hand, the 3 -agonist nalbzoh has been reported to exert an antagonist action at ORL 1 receptors (Dunnill et al., 1996) . Figure 3B 2 shows that 1 M nalbzoh almost completely prevented suppression of I Ba,T by 1 M nociceptin (n ϭ 3) (Fig. 3B 1 ) .
Nalbzoh also has significant antagonist action at -opioid receptors (Dunnill et al., 1996) , and we found that it antagonized the actions of both morphine and nociceptin on HVA I Ba (n ϭ 4).
Role of G-proteins
Agonist-modulation of N-type Ca 2ϩ channel currents via Gproteins is associated with slowing of the activation kinetics of the current as the channels are changed from a "willing" to a "reluctant" state (Bean, 1989; Dolphin, 1996) . This type of kinetic slowing has been reported for the action of nociceptin on HVA I C a in hippocampal neurons (Knoflach et al., 1996) . An obvious increase in the time constant for activation of H VA I Ba is seen in the presence of morphine or nociceptin in Figure 2 A 1 , B 1 . Suppression of H VA g Ba was relieved by 75 msec depolarizing prepulses to ϩ100 mV ( Fig. 2 A 2 , B 2 ). This type of facilitation, which is also characteristic of G-protein-coupled responses (Dolphin, 1996) , was reported previously by Womack and McCleskey (1995) for the action of the -opioid selective agonist PLO 17 (Tyr-Pro-N-Me-Phe-D-Pro-N H 2 ) on HVA I Ba in DRG.
The inactivation kinetics of g Ba,T prevented us from testing whether nociceptin suppression was relieved by a large depolarizing prepulse. There was no alteration, however, in the rate of activation of g Ba,T when it was recorded in the presence of nociceptin. Figure 4 A 1 illustrates moderate suppression of I Ba,T by 100 nM nociceptin. The data records were normalized to the same amplitude and replotted in Figure 4 A 2 . The two records superimpose exactly, indicating that the rate of onset of the current, as well as the rate of inactivation at Ϫ40 mV, is unchanged by nociceptin. This raised the possibility that its actions involve a novel, G-protein-independent mechanism. This possibility was tested by substituting 100 M GTP-␥-S for the GTP that was normally included in the pipette solution. If the action of nociceptin on I Ba,T did not involve a G-protein, it should produce reversible suppression of the current in the presence of GTP-␥-S (Moises et al., 1994a) . This seemed to be the case (n ϭ 5). We took advantage of the use of H VA I Ba as an internal positive control to demonstrate inhibition of G-protein inactivation by GTP-␥-S. A double-step protocol from Ϫ90 mV was used to activate g Ba,T at Ϫ40 mV and then to activate HVA g Ba at Ϫ10 mV. Figure 4 B 1 shows data from a cell studied with 100 M GTP-␥-S. The amplitudes of I Ba,T responses and HVA I Ba responses evoked once every 20 sec are plotted against time. Although the nociceptin-induced suppression of HVA g Ba was irreversible, as would be expected for a G-protein-coupled response, complete recovery of nociceptin suppression of I Ba,T was observed. Superimposed data records obtained before, during, and after nociceptin application are shown in Figure 4 B 2 . I Ba,T recovers after nociceptin has been washed out, but HVA I Ba does not. It may be noticed that nociceptin does not seem to invoke kinetic slowing of HVA I Ba in Figure 4 B 2 . This may reflect the presence of GTP-␥-S in the patch pipette.
GDP-␤-S irreversibly inactivates G-proteins (Burch and Axelrod, 1987) . As might be expected, replacement of GTP in the patch pipette with 2 mM GDP-␤-S prevented modulation of HVA g Ba by nociceptin. I Ba,T suppression in the same cell, at the same time, was unaffected (n ϭ 4). A typical experiment, using the double-pulse protocol to sequentially activate g Ba,T and HVA g Ba , is illustrated in Figure 5A . The superimposed records show that nociceptin suppresses I Ba,T but has no effect on HVA conductances.
G-protein function can also be modified radically by AlF 3 . This substance acts as the AlF 4Ϫ anion, which is an analog of the ␥-phosphate of GTP (Bigay et al., 1987) . AlF 3 therefore strongly activates G-proteins and thereby occludes the response of their downstream targets to agonists. In our experiments, HVA g Ba Figure 4 . Evidence against Gprotein involvement in the effect of nociceptin on T-currents. A 1 , Superimposed data records to show suppression of I Ba,T by 100 nM nociceptin.
A 2 , Superimposed records from A 1 normalized and replotted. Note that the two records superimpose exactly, and the presence of nociceptin does not slow the onset or the rate of inactivation of the current. B 1 , Graph of time course of an experiment done with a pipette containing 100 M GTP-␥-S. Points represent amplitudes of I Ba,T or H VA I Ba evoked by a double-pulse protocol applied once every 20 sec. Both I Ba,T and HVA I Ba are suppressed by 1 M nociceptin. Although I Ba,T returns to control amplitude after nociceptin washout, HVA I Ba remains suppressed throughout the course of the experiment. The cell had been left to stabilize with intracellularly applied GTP-␥-S for 15 min before the application of nociceptin. B 2 , Original superimposed data record collected before, during, and after application of nociceptin in the experiment plotted in B 1 . The cell was stepped from Ϫ90 to Ϫ40 mV to activate g Ba,T and then to Ϫ10 mV to activate HVA g Ba . Nociceptin invokes reversible suppression of the former and irreversible suppression of the latter. decreased to ϳ20% of control after ϳ20 min when 100 M AlF 3 was included in the patch pipette. I Ba,T was relatively stable under these conditions and was still susceptible to reversible suppression by nociceptin (n ϭ 4). A typical experiment is illustrated in Figure 5B . The superimposed records show that nociceptin reversibly suppresses I Ba,T when H VA conductances in the same cell are refractory to modulation by G-protein-coupled agonists.
Biophysical aspects of the action of nociceptin
Inhibition of I Ba,T by nociceptin did not exhibit "usedependence." Because the time constant for removal of I Ba,T inactivation at Ϫ90 mV is ϳ1 sec (C arbone and L ux, 1987) , we were unable to repeatedly activate the current, even with 30 msec pulses, at frequencies above 0.4 Hz. These brief pulses were used to limit the amount of inactivation that developed at Ϫ40 mV, so that less inactivation had to be removed between the pulses at Ϫ90 mV. When nociceptin was applied while I Ba,T was repeatedly evoked at 0.4 Hz, the current attained a reduced steady-state amplitude within 3 min of initiating nociceptin superfusion.
When nociceptin was washed out and reapplied in the absence of channel opening, a similar rate and extent of depression of I Ba,T was seen (n ϭ 4). The block was therefore not use-dependent. In the experiment illustrated in Figure 6 A, the downward deflections are low-speed chart recordings of successive current responses (I Ba,T ) to 30 msec pulses to Ϫ40 mV (from V h ϭ Ϫ90 mV) delivered at 0.4 Hz. The brief I Ba,T responses and the associated tail and capacitative currents cannot be distinguished on the chart. The progressive decrease in amplitude of the deflections reflects suppression of the current by nociceptin. When nociceptin is reapplied in the absence of repeated I Ba,T responses, the same amount of block still occurs at about the same rate.
In other experiments, in which both I Ba,T and HVA I Ba were recorded, there seemed to be a slight delay in the onset of block of HVA I Ba compared with I Ba,T .
We were also able to exclude an alteration in steady-state inactivation as the mechanism for a nociceptin-induced decrease in I Ba,T . Figure 6 B shows the steady-state inactivation curve for I Ba,T ; the current was evoked at Ϫ40 mV following steps from various prepulse potentials. The voltage protocol is shown as an inset to the graph. Maximal I Ba,T was evoked from holding potentials exceeding Ϫ105 mV, and currents evoked from different prepulse potentials were normalized to this maximal value. In the presence of 100 nM nociceptin, which reduced I Ba,T recorded at 40mV by 36%, there was no obvious change in the normalized steady-state inactivation curve. Original data records are shown in Figure 5C 1 ,C 2 . Similar effects were seen in a total of five cells.
Effect of nociceptin on action potentials and burst discharges
I C a,T plays a role in the production of burst discharges in various neuronal types (Huguenard, 1996) , and it has been reported to underlie an afterdepolarization that follows a single AP in some DRG neurons (White et al., 1989) . This afterdepolarization gives rise to a burst of two or more successive APs in response to a single brief stimulus. Typical current-clamp recordings from a cell of this type are shown in Figure 7 . The afterdepolarization and associated second and third spikes were attenuated by 1 M nociceptin (n ϭ 4) (Fig. 7A) but not by 1 M morphine (n ϭ 4) (Fig. 7B) . Figure 7C illustrates suppression of the afterdepolarization by Ni 2ϩ (100 M; n ϭ 4), a result consistent with the involvement of I C a,T in its generation (White et al., 1989) .
DISCUSSION
We find that the novel opioid peptide nociceptin selectively inhibits I Ba,T in medium-sized DRG neurons by a G-proteinindependent mechanism. This effect is reflected in impairment of the ability of the neurons to generate bursts of APs in response to a brief excitatory stimulus.
Unlike HVA g Ba , which is subject to regulation by a wide variety of neuromodulators that act through heptahelical, Gprotein-coupled receptors (Dolphin, 1996) , very few agonists have been reported to modulate I Ba,T (Kobrinsky et al., 1994; Huguenard, 1996) . Although I Ba,T in sensory neurons is decreased when G-proteins are activated with GTP-␥-S (Gross et al., 1990) , this mechanism does not seem to be involved in the action of nociceptin. Because the G-protein-mediated effects of opioid agonists on HVA g Ba are well characterized in DRG neurons (Moises et al., 1994a,b; Wilding et al., 1995; Womack and McCleskey, 1995) , each cell that was studied served as its own control. This allowed us to convincingly exclude a role for Gproteins, because nociceptin attenuated I Ba,T after its effects on Figure 5 . Further evidence against G-protein involvement in the effect of nociceptin on T-currents. A, Effect of 1 M nociceptin on I Ba,T and H VA I Ba in the same cell studied with 2 mM GDP-␤-S in the pipette. The cell had been allowed to equilibrate with intracellularly applied GDP-␤-S for 15 min before the application of nociceptin. Superimposed records acquired before and during nociceptin application show that I Ba,T was suppressed when HVA I Ba was unaffected. B, An experiment similar to that of A but using AlF 3 (100 M) instead of GDP-␤-S in the pipette. The cell had been allowed to equilibrate with intracellularly applied AlF 3 for 20 min before the application of 1 M nociceptin. Superimposed records acquired before, during, and after nociceptin application show that I Ba,T was reversibly suppressed when H VA I Ba was unaffected. Voltage protocol in B applies also to experiment illustrated in A.
HVA g Ba were compromised with GDP-␤-S or AlF 3 (Fig. 5) . Similarly, in cells in which G-protein-coupled effects of nociceptin on H VA g Ba were rendered irreversible by the inclusion of GTP-␥-S in the pipette, nociceptin invoked a reversible suppression of I Ba,T (Fig. 4 B) . The fact that nociceptin clearly altered the activation kinetics of H VA g Ba (Fig. 2 A) yet failed to alter that of g Ba,T (Fig. 4 A) may also be consistent with modulation of T-type Ca 2ϩ channels by a G-protein-independent mechanism (but see Kobrinsky et al., 1994) .
Nociceptin was identified as an endogenous opioid agonist for the heptahelical ORL 1 receptor (Meunier et al., 1995; Reinscheid et al., 1995; Nothacker et al., 1996) , and Connor et al. (1996b) showed that its effects on C a 2ϩ channel currents and intracellular Ca 2ϩ accumulation in neuroblastoma cells are blocked by pertussis toxin. Because the effects of nociceptin on I Ba,T in DRG neurons do not seem to involve G-proteins, this raises the possibility that they may not be mediated via the heptahelical ORL 1 receptor. Although the effect of nociceptin is antagonized by nalbzoh (Fig. 2 B) (Dunnill et al., 1996) , the selectivity of this antagonist is yet to be established. On the other hand, the EC 50 for the action of nociceptin on I Ba,T of 100 nM is comparable with that for its presumed actions at ORL 1 receptors (22-90 nM) (Connor et al., 1996a,b; Vaughan and Christie, 1996; . In our opinion, neither the effect of nalbzoh nor the similarities in EC 50 values allow the unequivocal implication or exclusion of a role for ORL 1 in the actions of nociceptin on I Ba,T . One remote possibility is that the activated ORL 1 receptor interacts directly with the T-type C a 2ϩ channel without the intervention of a G-protein. Schroeder et al. (1991) reported that g C a,T in sensory neurons is attenuated by the -receptor selective agonist D-Ala 2 , N-MePhe 4 -Gly 5 -ol enkephalin (DAMGO). It is therefore possible that only certain opioid peptides attenuate I Ba,T and that this action is not shared by other opioids, including PLO17 (Moises et al., 1994b) and morphine. It therefore would be of interest to determine whether the action of DAMGO on T-channel currents described by Schroeder et al. (1991) is G-protein-mediated and whether it is blocked by naloxone. This antagonist was ineffective in antagonizing the action of nociceptin on I Ba,T (Fig. 2 A) . Two other reports of effects of opioid peptides that do not seem to involve G-proteins have already appeared. Twitchell and Rane (1994) were unable to implicate G-proteins in the potentiation of Ca 2ϩ -sensitive K ϩ current by the -selective agonist DAMGO, and Brauneis et al. (1996) showed that dynorphin inhibited currents through recombinant NMDA channels expressed in Xenopus oocytes that did not express opioid receptors. Perhaps Gprotein-independent actions contribute to behavioral effects seen with opioid peptides in whole animals. Thus, suppression of I C a,T by nociceptin may contribute to the hyperalgesic effect seen in tail-flick tests when it is administered intracerebroventricularly to mice (Meunier et al., 1995; Reinscheid et al., 1995) .
Little can be said, at this stage, about the molecular mechanism of the action of nociceptin. Because effects on steady-state inactivation and effects mediated via G-proteins have been excluded, nociceptin may interact directly with the T-type Ca 2ϩ channel. Because the EC 50 is 100 nM, this would predict a residency time ( T) of ϳ100 msec on its receptor site. This was estimated by assuming a K D of 10 Ϫ7 that is equal to the EC 50 and using the approximation that T ϭ 10 Ϫ8 /K D (Hille, 1992) . A relatively long residency time suggests that nociceptin would not produce a "flickering" type of open-channel block, and this is consistent with the observation that it did not affect the rate of activation or inactivation of I Ba,T (Fig. 4 A 2 ) . Direct interaction of nociceptin with T-type Ca 2ϩ channels could therefore involve "closed- channel block," as has been proposed for ethosuximide block of thalamic channels (Coulter et al., 1991) , or a very rapidly developing block of open channels in which the peptide would enter each channel as soon as it opens and prevent the passage of ions. In either case, no use-dependence would be observed. Activation of a receptor tyrosine kinase is another plausible, G-protein-independent mechanism for the action of a peptide such as nociceptin. The possible relevance of this mechanism derives from the observation that H VA I C a in molluscan neurons is enhanced within minutes of application of mammalian nerve growth factor (Wildering et al., 1995) . Also, peptides such as angiotensin II and vasopressin can act via tyrosine kinase pathways to cause contraction of certain types of smooth muscle (Hollenberg, 1994) . A third possibility is that nociceptin exerts its effects via activation of membrane-bound guanylyl cyclase in the same way as atrial natriuretic factor (Fenrick et al., 1994) . These and other possible mechanisms could be readily examined in future work; it may be that the preservation of a nociceptin response in the presence of GTP analogs and AlF 3 precludes a role for the direct activation of guanylyl cyclase.
The observation that I Ba,T in DRG is blocked by nociceptin but not by ethosuximide may reflect differences in the properties of the T-type Ca 2ϩ channels in thalamic neurons compared with sensory neurons. This goes along with the idea that several subtypes of T-channels exist in neurons (Kobrinsky et al., 1994; Huguenard, 1996) .
Because I C a,T is responsible for generating repetitive or bursting discharges, for boosting Ca 2ϩ entry, and for low-threshold spike generation (Huguenard, 1996) , it can contribute to convulsant activity in central neurons. The medium-sized DRG neurons used in the present study also tend to exhibit short bursts of 2-4 APs in response to a brief depolarizing stimulus. This burst of APs originates from an afterdepolarization that follows the first AP. Our results (Fig. 7C) with the T-channel blocker Ni 2ϩ (DeWaard et al., 1996) support the hypothesis that I C a,T underlies the generation of this afterdepolarization (White et al., 1989) . Because nociceptin binding sites have been detected in various CNS regions, including cortex and thalamus (Sim et al., 1996) , the observation that nociceptin blocks both I Ba,T and bursting activity (Fig. 7) raises the possibility that it may be an endogenous anticonvulsant. Because nociceptin blocks I Ba,T in a cell type in which ethosuximide is ineffective, the development of appropriate nociceptin analogs may provide a logical route for the development of new anticonvulsant therapies. Figure 7 . Effects of nociceptin, morphine, and Ni 2ϩ on APs, bursting activity, and afterdepolarizations. All records were obtained from the same cell. APs were evoked from a 5 msec /0.3 nA depolarizing current command applied via the recording electrode. Superimposed records of bursts of APs were recorded before and during superf usion of ( A) 1 M nociceptin, ( B) 1 M morphine, and ( C) 100 M Ni 2ϩ . Note that afterdepolarization and burst of spikes are attenuated by nociceptin and Ni 2ϩ but not by morphine. C alibration (40 mV/40 msec) in B and current trace in C apply to all records.
